OpGen WKN: A2PQ6B ISIN: US68373L3078 Forum: Aktien Thema: Hauptdiskussion

Moin, auf welcher Grundlage habt ihr eicebtlich eure Longlong Entscheidung getroffen? Ich verloere die Geduld- ist leider wie einige Bios in die Hose gegangen- also raus- oder mache ich den schlimmsten Fehler meines Lebens? 🤷‍♂️

aaaaah 🤣🤣🤣

Hm... Ignore... 😏🙄🙄

Was soll hmar maker bedeuten?

Nö ich bin nicht raus. Ich bleibe investiert und solange der Hmar Maker, also Du, weiter trollst, dann lass ich Dich alleine spielen 😁👍

Maker?

Maker wenn Interessiert das ?

Und Adler is hier wohl rechtzeitig raus oder meldet er sich nur wenn es nach Norden steil geht 😇

Seit 6M seitwärts ist n schöner Mist

LongLong... bin gespannt

Ich habe den Verlauf hoch gerechnet. Gut möglich das wir da schon nächste Woche ausbrechen, also kürzer als 12 Tage. Der Kurs heute hält sich ganz ordentlich.

Wie kommst Du auf die 12 Tage?

So, ich wollte mich auch mal wieder melden bezüglich des Chart Bild. Selbst die Nachricht von gestern hat den Kurs nicht interessiert, auch VK und Käufe der letzten Tage wurden neutralisiert. Der Kurs wird noch ca. 12 Tage brauchen um aus einem aktuellen Flaggen Muster durchzubrechen. Was danach ist kann aktuell keiner sagen, der Wochenchart ist in einer Seitwärtsbewegung die von 1,60 bis 2,80 $ reicht. In diesem Jahr wird wohl nichts mehr passieren, hoffen wir auf das nächste Jahr.

Durch Google übersetzen lassen😊😊😊

Hört sich gut an oder?kann nicht so gut englisch

Extended collaboration with leading global generics company Sandoz for optimal antibiotic drug positioning by predictive antibiotic susceptibility testing Presenting study on combining ares-genetics.cloud with long-read sequencing for rapid antibiotic susceptibility testing in collaboration with Johns Hopkins researchers Expects granting of key patent on genetic resistance prediction against antimicrobial drugs GAITHERSBURG, Md. and VIENNA, Austria, Dec. 01, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that its group company and wholly owned subsidiary Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”) has extended its collaboration with Sandoz within its pharma partnering program. Also, Ares Genetics expects to present advances of its research use only (RUO) based ares-genetics.cloud platform for predictive antibiotic susceptibility testing (AST) at various scientific conferences and expects granting of key patent on genetic resistance prediction. Ares Genetics and Sandoz, the #1 supplier of generic antibiotics globally, have extended their collaboration under a strategic collaboration agreement with the overall goal to develop a digital anti-infectives platform combining established microbiology laboratory methods with advanced bioinformatics and artificial intelligence methods to support drug development and life cycle management. The next phase of the collaboration aims at further leveraging molecular predictive AST and follows the presentation of final results from the initial collaboration phase on optimal positioning of fosfomycin and fosfomycin combination therapies by molecular antibiotic susceptibility testing and in silico modeling at the Antimicrobial Resistance – Genomes, Big Data and Emerging Technologies virtual conference in early November of this year. Recent advances of Ares Genetics’ ares-genetics.cloud platform enabling accurate and rapid next-generation sequencing (NGS)-based AST using Oxford Nanopore Technology long-read sequencing are scheduled to be presented at the virtual Sequencing, Finishing and Analysis in the Future Meeting, from December 1 to 3, by Ares Genetics’ Head of Bioinformatics & Analytics Dr. Stephan Beisken, who leads the development. In addition, data is scheduled to be presented at the ASM Conference on Rapid Applied Microbial Next-Generation Sequencing and Bioinformatics Pipelines, from December 7 to 11 by, Dr. Patricia Simner from Johns Hopkins Medicine, who collaborates with the Ares Genetics team on developing next-generation sequencing based antibiotic susceptibility testing solutions. Alongside these latest technology development achievements, Ares Genetics has further expanded its intellectual property (IP) portfolio and technology position in data-driven infectious disease diagnostics and recently received communication that the examining division of the European Patent Office intends to grant a European patent for European Patent Application No. 16 751 551.9 “Genetic resistance prediction against antimicrobial drugs in microorganism using structural changes in the genome.” “We’re thrilled about our continued progress in developing and commercializing much needed solutions for rapid predictive antibiotic susceptibility testing using next-generation sequencing as well as the growing demand for our testing-as-a-service and interpretation-as-a-service offerings enabled by patent-pending AI-powered technology,” commented Dr. Andreas Posch, CEO Ares Genetics. He added, “I am particularly excited about our collaboration with Sandoz on optimal antibiotic drug positioning based on molecular testing as well as our joint work with Johns Hopkins demonstrating feasibility of accurate AST prediction using long-read sequencing technology as this technology could potentially allow for rapid predictive AST directly from native patient samples.”